Pratt, Daniel S.
Beth Israel Deaconess Medical Center · Massachusetts General Hospital
7 papers on CoChatORCID 0000-0002-7426-969X
Most cited papers
- Verified
Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients
Pratt, D. S., & Kaplan, M. M. (2000) · New England Journal of Medicine
Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects
Cited by 1,203
- Verified
Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
Fix, O. K., Hameed, B., Fontana, R. J., Kwok, R. M., McGuire, B. M., Mulligan, D. C., Pratt, D. S., Russo, M. W., Schilsky, M. L., Verna, E. C., et al. (2020) · Hepatology
COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies
Cited by 473
- Verified
Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial
Allegretti, J. R., Kassam, Z., Carrellas, M., Mullish, B. H., Marchesi, J. R., Pechlivanis, A., Smith, M., Gerardin, Y., Timberlake, S., Pratt, D. S., et al. (2019) · American Journal of Gastroenterology
Liver Diseases and ImmunityGut microbiota and health
Cited by 234
- Verified
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
Schattenberg, J. M., Pares, A., Kowdley, K. V., Heneghan, M. A., Caldwell, S., Pratt, D., Bonder, A., Hirschfield, G. M., Levy, C., Vierling, J., et al. (2021) · Journal of Hepatology
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 191
- Verified
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 127
- Verified
Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases
Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology
Liver Diseases and ImmunityInflammatory Bowel Disease
Cited by 105
- Verified
Long‐term clinical impact and cost‐effectiveness of obeticholic acid for the treatment of primary biliary cholangitis
Samur, S., Klebanoff, M., Banken, R., Pratt, D. S., Chapman, R., Ollendorf, D. A., Loos, A. M., Corey, K., Hur, C., & Chhatwal, J. (2017) · Hepatology
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 89
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free